The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001

AIDS

Volumn 18, Issue 18, 2004, Pages 2411-2418

  Beck, Eduard J ^a,b,e   Mandalia, Sundhiya ^c   Gaudreault, Maurice ^a   Brewer, Carl ^b   Zowall, Hanna ^b   Gilmore, Norbert ^b   Klein, Marina B ^b   Lalonde, Richard ^b   Piché, Alain ^d   Hankins, Catherine A ^a,b  

^a Dept de S Pub de Montreal Ctr ^*  (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

CDC stage of HIV infection; Cost effectiveness; Highly active antiretroviral therapy; Life year gained; Use and costs services

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CANADA; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG USE; FEMALE; HEALTH CARE COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; SEXUAL ORIENTATION; T LYMPHOCYTE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHI-SQUARE DISTRIBUTION; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG COSTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; QUALITY-ADJUSTED LIFE YEARS; QUEBEC;

EID: 19944427643     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. NIAID AIDS Agenda. New Findings bring Hope to Vancouver AIDS Conference. September 1996. http://www.naid.nih.gov/publications/agenda/0996/page1.htm (accessed 10/3/2004).
2. Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug resistant HIV infection in North and South America. N Engl J Med 2003; 348:2175-2185.
3. Krentz HB, Auld MC, Gill MJ for the HIV Economics Study Group. The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001. CMAJ, 2003; 169:106-110.
4. Beck EJ, Miner AH. Effectiveness and efficiency in the delivery of HIV services: economic and related considerations. In: Gazzard BG, Johnson M, Miles A (editors): The Effective Management of HIV/AIDS. UK Key Advances in Clinical Practice. London: Aesculapius Medical Press; 2001. pp. 113-138
5. Beck EJ, Whitaker L, Kennelly J, McKevitt L, Wadsworth J, Miller DL, et al. Changing presentation and survival, service utilization and costs for AIDS patients: insights from a London referral centre. AIDS, 1994; 8:379-384.
6. Beck EJ, Kennelly J, McKevitt C, Whitaker L, wadsworth J, Miller DL, et al. Changing use of hospital services and costs at a London AIDS referral center, 1983-1989. AIDS 1994; 8:367-377.
7. Beck EJ, Tolley K, Power A, Madalia S, Rutter P, Izumi J, et al for the NPMS Steering Group. Use and cost of HIV service provision in England. Pharmacoeconomics 1998; 14:639-652.
8. Beck EJ, Mandalia S, Williams I, Power A, Newson R, Molesworth A, et al for the NPMS Steering Group. Decreased morbidity and use of hospital services in English HIV infected individuals with increased uptake of anti-retroviral therapy 1996-1997. AIDS 1999; 13:2157-2164.
9. Canadian Institute for Health Information. DAD Resource Intensity Weights and Expected Length of Stay 2002. Ottawa: Canadian Institute for Health Information; 2002.
10. Ontario Ministry of Health and Long-Term Care. Schedule of Benefits for Physician Services under the Health Insurance Act. April 1, 2002. Ottawa: Ontario Ministry of Health and Long-Term Care 2003.
11. Regie de l'assurance maladie du Quebec. Manuel des Medecins Specialistes. RAMQ, Quebec. Regie de l'assurance maladie du Quebec 2003.
12. Regie de l'assurance maladie du Quebec. Manuel des Medecins Specialistes. Services de laboratoire en etablissement. RAMQ, Quebec. Regie de l'assurance maladie du Quebec. Quebec: 2003.
13. Regie de l'assurance maladie du Quebec. Manuel des Medecins Omipracticiens. RAMQ, Quebec. Regie de l'assurance maladie du Quebec. Quebec: 2003.
14. IMS Health. Canadian CompuScript October 2001. Pointe Claire, Quebec: IMS Canada 2001.
15. Ontario Ministry of Health and Long-Term Care. Ontario Health Insurance Schedule of Benefits and Fees: Schedule of Benefits for Laboratory Services. April 1, 2002. Ottawa: Ontario Ministry of Health and Long-Term Care 2003.
16. Ministere de la sante et des services sociaux. Laboratoires de biologie medicale: measure de la production 2003-2224. Ministere de la sante et des services sociaux 2003.
17. Drummond, M.F., O'Brien, B., Stoddart, G.L., Torrance, G.W. Methods for the economic evaluation of health care programmes - 2nd Edition, Oxford: Oxford University Press, 1997:52-53.
18. Statistics Canada. CANSIM Matrix P100200. . Ottawa: Statistics Canada 2003.
19. Bank of Canada. Average Canadian - US Dollar Exchange rate 2002. http://www.bank-banque-canada.ca/cgi-bin/famecgi.fdps (accessed 31 July 2004).
20. Tramarin A, Campostrini S, Postma MJ, Calleri G, Tolley K, Parise N, et al. A multicentre study of patient survival, disability, quality of life and cost of care: among patients with AIDS in northern Italy. Pharmacoeconomics, 2004; 22:43-53.
21. Krentz H, Gill MJ, De Forest J. The impact of AIDS on the direct cost of medical care since the introduction of highly active antiretroviral therapy (HAART). Can J Infect Dis 2004; Suppl 15:60A [abstract 337P].
22. Stoll M, Class C, Schutle E, Graf Von Der Sculenburg JM, Schmidt RE. Direct costs for the treatment of HIV-infection in a German cohort after introduction of HAART. Eur J Med Res 2002; 7:463-471.
23. Mandalia S, Parmar D, Fisher M, Pozniak A, Tang A, Youle M, et al. on behalf of the NPMS-HHC Steering Group. Correlation between CD4 response and cost of hospital treatment in antiretroviral naïve hiv infected patients started on triple HAART. XIV International AIDS Conference, Barcelona, Spain, July 2002 [abstract ThPeA7023].
24. Krenz HB, Auld MC, Gill MJ. The high cost of medical care for patients who present later (CD4 < 200 cells/μl) with HIV infection. HIV Med 2004; 5:93-98.
25. Tousignant P, Lavoie G, Poirier L-R, Lamontagne D, Dupont MA, Roy D. Évaluation de l'impact de la reconfiguration du réseau sur la santé et le bien-être de la population de Montréal-Centre: Résultats du monitorage. Montreal: Direction de la santé publique, RRSSS-Montréal-Centre, 2000.
26. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992; 146 :473-481.
27. Anis AH, Guh D, Hogg RS, Wang X, Yip B, Craib KJP, et al. The cost effectiveness of antiretroviral regimes for the treatment of HIV/AIDS Pharmacoeconomics 2000; 18:393-404.
28. Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seager GR, et al. The cost effectiveness of combination anti-retroviral therapy for HIV disease. N Engl J Med 2001; 344: 824-831.
29. Sendi PP, Bucher HC, Harr T, Craig BA, Schwietert M, Pfluger D, et al. on behalf of the Swiss HIV Cohort Study. Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. AIDS 1999; 13:1115-1122.
30. Schackman BR, Goldie SJ, Weinstein MC, Losina E, Zhang H, Freedberg KA. Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults. Am J Public Health 2001; 91:1456-1463.
31. Schackman BR, Freedberg KA, Weinstein MC, Sax PE, Losina E, Zhang H, et al. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Arch Intern Med 2002; 162:2478-2486.
32. Schackman BR, Goldie SJ, Freedberg KA, Losina E, Brazier J, Weinstein MC. Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making 2002; 22:27-38.
33. Moore RD, Bartlett JG. Combination antiretroviral therapy in HIV infection. An economic perspective. PharmacoEconomics 1996; 10:109-113.
34. Cook J, Dasbach E, Coplan P, Monkson L, Yin D, Meibohm A et al. Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial. AIDS Res Hum Retroviruses 1999; 15:499-508.
35. Miners AH, Sabin CA, Trueman P, Youl M, Mocroft A, Johnson M. et al. Assessing the cost-effectiveness of HAART for adults with HIV in England. HIV Med 2001; 2:52-58.
36. Trueman P, Youle M, Sabin CA, Miners AH, Beck EJ. The cost-effectiveness of triple nucleoside analogue therapy antiretroviral regimens in the treatment of HIV in the United Kingdom. HIV Clin Trials 2000; 1:27-35.
37. Harling G, Wood R, Beck EJ. The Efficiency of Interventions in HIV Infection: a review from institutional and community perspectives. Disease Management of Health Outcomes (Accepted for publication).
38. Mullins CD, Whitelaw G, Cooke JL, Beck EJ. The indirect cost of HIV infection in England. ClinTherapeut 2000; 22:1333-1345.
39. Beck EJ, Mandalia S. The cost of HIV treatment and care in England since HAART: Part 1. Br J Sexual Med 2003; 27:19-23.
40. Youle M. Salvage treatment in HIV disease. Int J STD & AIDS 2001; 12:286-293.
41. Beck EJ, Miners AH, Tolley K. The cost of HIV treatment and care: a global review. PharmacoEconomics 2001; 19:13-39.
42. Beck EJ, P Robillard P, Coté P, et al. Réseau Informatique de Sida au Québec. Montreal, Canada: Unité Maladies Infectieuses, Direction de la santé publique, Regie Regionale de la Sante et Des Services Sociaux De Montreal-Centre, 2001.
43. Ontario HIV Treatment Network. http://www.ohtn.on.ca/hiipfacts.html. (accessed 29 May 2004).
44. Direction des Hospitaux, Mission SIDA. DMI2: an Information System Built Around the Patient. INSERM - SC4. Paris, France: Ministere de la Sante et de l'action Humanitaire, 1993.
45. De Wolf F, Lange JMA, Bossuyt PMM, et al for the Athena Project. Monitoring of Human Immunodeficiency Virus Type-1 (HIV-1) Infection in the Netherlands. Amsterdam: Stichting HIV Monitoring, Natec, AMC; 2001.
46. Beck EJ, Mandalia S. The cost of HIV treatment and care in England since HAART: Part 2. Br J Sexual Med 2003; 27:21-23.
47. WHO Scaling up Antiretroviral Therapy in Resource-limited Settings: Treatment for a Public Health Approach. 2003 revision. Geneva 2004 http://www.who.int/hiv/pub/prev_care/en/arv revision2003en.pdf (accessed 4 June 2004).
48. Beaglehole R, Bonita R. Public Health at the Crossroads: Achievements and Prospects. Cambridge, UK: Cambridge University Press; 1997, pp. 124-125.